Inquiry Basket
CAS No.: 2281797-55-3
Cat No.: BADC-01094
Purity: >98.0%
4.5 
mDPR(Boc)-Val-Cit-PAB is a protected cleavable ADC linker with Val-Cit dipeptide and PAB spacer, designed for controlled enzymatic payload release and site-specific conjugation in antibody-drug conjugates.
Structure of 2281797-55-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
mDPR(Boc)-Val-Cit-PAB, a specialized linker molecule utilized in drug development, particularly in the creation of antibody-drug conjugates (ADCs), boasts a diverse array of applications.
Antibody-Drug Conjugate Development: An integral component in the realm of ADC development, mDPR(Boc)-Val-Cit-PAB serves as the linchpin connecting potent cytotoxic drugs to specific antibodies. Engineered for stability in the bloodstream yet enabling precise drug release within target cancer cells, this linker facilitates targeted delivery, thus minimizing systemic toxicity and amplifying therapeutic efficacy.
Cancer Research: In the expansive landscape of cancer research, mDPR(Boc)-Val-Cit-PAB takes center stage as a tool for dissecting targeted drug delivery mechanisms. Researchers harness this linker to scrutinize the ability of ADCs to selectively transport chemotherapy drugs to cancerous cells while sparing healthy tissues. These inquiries are pivotal in advancing the development of safer and more potent cancer therapies.
Bioconjugation Techniques: At the nexus of bioconjugation techniques, mDPR(Boc)-Val-Cit-PAB emerges as a pivotal facilitator for attaching diverse bioactive molecules to antibodies or other targeting entities. Its versatility empowers the creation of intricate bioconjugates with far-reaching implications across diagnostics, therapeutic monitoring, and personalized medicine. This linker enhances the functional repertoire of conjugated molecules, broadening their applications in the dynamic realm of biomedical research.
Pharmaceutical Manufacturing: Within the sphere of pharmaceutical manufacturing, mDPR(Boc)-Val-Cit-PAB assumes a critical role in the synthesis of stable and efficacious drug conjugates. This linker guarantees the secure attachment of payloads during production, ensuring their integrity through formulation and storage. Such stability is paramount for upholding the potency and consistency of the final therapeutic product, thereby securing reliable and robust clinical outcomes.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
| BADC-00929 | Fmoc-D-Val-Cit-PAB | 1350456-65-3 | |
| BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
| BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
| BADC-00958 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | |
| BADC-00708 | Val-cit-PAB-OH | 159857-79-1 | |
| BADC-00968 | MC-Val-Cit-PAB | 159857-80-4 | |
| BADC-00364 | Fmoc-Val-Cit-PAB | 159858-22-7 | |
| BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
| BADC-01745 | MC-Val-Cit-PAB-NH-C2-NH-Boc | 1616727-22-0 |
What is mDPR(Boc)-Val-Cit-PAB used for in ADCs?
mDPR(Boc)-Val-Cit-PAB is a cathepsin-cleavable linker used to attach payloads to antibodies. The Val-Cit-PAB motif is enzymatically cleaved within lysosomes, enabling selective intracellular release of cytotoxic agents for targeted therapy.
11/9/2022
We are interested in how the Boc-protected mDPR group affects linker stability.
The Boc-protection increases linker stability during storage and conjugation processes. It prevents premature cleavage or side reactions, ensuring consistent ADC production and reliable payload delivery.
1/12/2019
Dear BOC Sciences, what role does the Val-Cit-PAB motif play in mDPR(Boc)-Val-Cit-PAB?
The Val-Cit-PAB motif is recognized and cleaved by lysosomal cathepsins. This cleavage releases the payload selectively in target cells, enhancing therapeutic specificity and reducing systemic toxicity.
4/8/2021
Good morning! Which payloads are compatible with mDPR(Boc)-Val-Cit-PAB?
It is compatible with thiol-containing cytotoxic payloads such as auristatins and maytansinoids. The linker ensures stable conjugation and controlled release, making it suitable for ADC development.
21/11/2019
Dear BOC Sciences, what storage and handling practices do you recommend to ensure the stability of mDPR(Boc)-Val-Cit-PAB?
mDPR(Boc)-Val-Cit-PAB should be stored at -20°C in a dry environment, protected from light and moisture. Minimizing exposure during handling preserves Boc protection and linker integrity. Use of aliquots is recommended for repeated experiments to maintain reliable conjugation performance.
11/5/2021
— Dr. Natalie Brown, Bioconjugation Scientist (USA)
mDPR(Boc)-Val-Cit-PAB linker exhibited high stability and reactivity, allowing efficient ADC payload attachment.
4/8/2021
— Prof. Henrik Larsen, Medicinal Chemist (Denmark)
Batch-to-batch consistency of mDPR(Boc)-Val-Cit-PAB was excellent, supporting reliable scale-up.
11/5/2021
— Dr. Sofia Moretti, Protein Chemist (Italy)
The Boc-protected linker maintained integrity under conjugation conditions. Very high quality.
21/11/2019
— Ms. Emily Thompson, R&D Manager (UK)
BOC Sciences delivered mDPR(Boc)-Val-Cit-PAB on schedule with complete analytical documentation.
11/9/2022
— Dr. Marcus Schmidt, Bioconjugation Specialist (Germany)
Using this linker improved payload stability and reproducibility across multiple ADCs.
— Mr. Daniel Johnson, Research Scientist (Canada)
High-quality mDPR(Boc)-Val-Cit-PAB facilitated smooth ADC development and workflow efficiency.
1/12/2019
mDPR(Boc)-Val-Cit-PAB
Required fields are marked with *
mDPR(Boc)-Val-Cit-PAB
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
